Business
Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates
Company Plans to File Q3 2019 10-Q on November 14, 2019SAN FRANCISCO, CA / ACCESSWIRE / November 12, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Company Plans to File Q3 2019 10-Q on November 14, 2019SAN FRANCISCO, CA / ACCESSWIRE / November 12, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today announced that Company management will host a conference call on Thursday, November 14th, 2019 at 9 a.m. Eastern Time to provide updates regarding the interim analysis of the third-party, investigator-initiated Phase 2 HALT-D study evaluating Mytesi® (crofelemer) for prevention and prophylaxis of diarrhea in breast cancer patients, and to review financials and business updates for the third quarter of 2019. Mytesi (crofelemer) is Jaguar's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.On November 14, 2019 the Company plans to file with the U.S. Securities and Exchange Commission its quarterly report on Form 10-Q for the three months ended September 30, 2019.Dial-In Instructions for Conference CallWhen: November 14, 2019 at 9 a.m. Eastern TimeDial-in (US Toll Free): 800-289-0438Dial-in (International): 323-794-2423Conference ID number: 3702255Live webcast on the investor relations section of Jaguar's website (click here)Replay InstructionsDial-in (US Toll Free): 844-512-2921Dial-in (International): 412-317-6671Replay Pin Number: 3702255Replay of the webcast on the investor relations section of Jaguar's website (click here)About Jaguar Health, Inc.Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.About Mytesi®Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule ou...